
Systems, Not Models: Generative AI Across the Drug Development Pipeline with Dov Gertz
Dov Gertz, co-founder and CEO of Converge Bio, is building a generative AI lab for the life sciences, with AI systems that plug directly into drug development workflows, from target discovery to antibody design to manufacturing.
We discuss why generative AI in biology needs systems rather than single models, where de novo design is overhyped, and how Converge's antibody system layers physics-based docking on top of generative models. Dov also explains how on-demand biobetters could reshape an industry built on patent expiration.
From discovering novel CRISPR systems with machine learning to building Converge across Tel Aviv and Boston, Dov shares lessons on following your passion, building talent density, and why engineers entering bio need more biology than they think.
More episodes from "The Bits in Bio Podcast"



Don't miss an episode of “The Bits in Bio Podcast” and subscribe to it in the GetPodcast app.








